GSK (GSK) plc announced that it has completed the acquisition of IDRx, Inc., a Boston-based, clinical-stage biopharmaceutical company dedicated to developing precision therapeutics for the ...

GSK plc (LSE/NYSE: GSK) today announced that it has completed the acquisition of IDRx, Inc. (IDRx), a Boston-based, clinical-stage biopharmaceutical company dedicated to developing precision ...

GSK completes acquisition of IDRx, Inc. GSK plc (LSE/NYSE: GSK) today announced that it has completed the acquisition of IDRx, Inc. (IDRx), a Boston-based, clinical-stage biopharmaceutical company ...

IDRx's lead molecule, IDRX-42, is an investigational tyrosine kinase inhibitor (TKI) targeting all clinically relevant primary and secondary KIT mutations in GIST. GIST is the most common form of ...

GSK plc announced that it has completed the acquisition of IDRx, Inc. (IDRx), a Boston-based, clinical-stage biopharmaceutical company dedicated to developing precision therapeutics for the treatment ...

(Alliance News) - GSK PLC on Monday said it has completed the acquisition of Boston, Massachusetts-based precision therapeutics firm IDRx Inc, adding to its growing portfolio of treatments for ...

Today, GSK plc (LSE/NYSE: LON:GSK), a prominent pharmaceutical company with a market capitalization of $74.88 billion and impressive gross profit margins of 71.81%, announced the completion of its ...

Biopharma deal activity climbed in early 2025, reaching $37.38 billion in the first two months, up from $35.66 billion a year ago. February saw $8.76 billion in deals, down 69% from January’s $28.63 ...